Cargando…
1775. Microbiome-Based Classifiers Accurately Differentiate Infectious Diarrhea From Functional Gastrointestinal Disorders and Provide Population-Scale Confidence Measures of Fecal Microbiota Restoration in Recurrent C. DifficileInfection
BACKGROUND: Fecal microbiota therapy is being actively pursued as treatment for recurrent C. difficile infection (rCDI), as well as for other GI disease indications associated with dysbiosis, for example, irritable bowel syndrome (IBS). RBX2660 is a microbiota-based drug designed to restore a health...
Autores principales: | Wu, Qinglong, Ross, Cana, Jones, Courtney, Blount, Ken, Savidge, Tor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252580/ http://dx.doi.org/10.1093/ofid/ofy209.160 |
Ejemplares similares
-
Faecal transplantation in a two‐year‐old child with therapy‐resistant Clostridiodes difficileinfection
por: Stenberg, Reidun, et al.
Publicado: (2022) -
Fecal Microbiota of Toxigenic Clostridioides difficile-Associated Diarrhea
por: Hernández, Marta, et al.
Publicado: (2019) -
The Enterotoxicity of Clostridium difficile Toxins
por: Sun, Xingmin, et al.
Publicado: (2010) -
Bile acid-independent protection against Clostridioides difficile infection
por: Aguirre, Andrea Martinez, et al.
Publicado: (2021) -
Is Fecal Leukocyte Test a good predictor of Clostridium difficile associated diarrhea?
por: Reddymasu, Savio, et al.
Publicado: (2006)